Characteristics of TAV- and BAV-associated thoracic aortic aneurysms-Smooth muscle cell biology, expression profiling, and histological analyses

Atherosclerosis

Volumn 220, Issue 2, 2012, Pages 355-361

  Blunder, Stefan ^a,b   Messner, Barbara ^a   Aschacher, Thomas ^a   Zeller, Iris ^a   Türkcan, Adrian ^a   Wiedemann, Dominik ^a   Andreas, Martin ^a   Blüschke, Gert ^b   Laufer, Günther ^a   Schachner, Thomas ^b   Bernhard, David ^a  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b INNSBRUCK MEDICAL UNIVERSITY   (Austria)

Author keywords

Metabolism; Migration; Osteopontin; Primary cultured aortic smooth muscle cells; Proliferation; Telomere; TIMP3

Indexed keywords

OSTEOPONTIN; TISSUE INHIBITOR OF METALLOPROTEINASE 3;

ADULT; AGED; AORTA ANEURYSM; ARTICLE; CELL METABOLISM; CELL MIGRATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOLOGY; GENE EXPRESSION; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MITRAL VALVE; PATHOGENESIS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; SMOOTH MUSCLE FIBER; TELOMERE; THORACIC AORTIC ANEURYSM; TRICUSPID VALVE;

ADULT; AGED; AORTA, THORACIC; AORTIC ANEURYSM, THORACIC; AORTIC VALVE; AUSTRIA; BLOTTING, WESTERN; CASE-CONTROL STUDIES; CELL MOVEMENT; CELL PROLIFERATION; CELLS, CULTURED; ELASTIC TISSUE; FIBROBLASTS; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; HEART DEFECTS, CONGENITAL; HUMANS; IMMUNOHISTOCHEMISTRY; MIDDLE AGED; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; OSTEOPONTIN; REAL-TIME POLYMERASE CHAIN REACTION; RNA, MESSENGER; TELOMERE SHORTENING; TIME FACTORS; TISSUE INHIBITOR OF METALLOPROTEINASE-3;

EID: 84855926435     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2011.11.035     Document Type: Article

References (33)

1. Elefteriades J.A., Farkas E.A. Thoracic aortic aneurysm clinically pertinent controversies and uncertainties. J Am Coll Cardiol 2010, 55:841-857.
2. Bickerstaff L.K., Pairolero P.C., Hollier L.H., et al. Thoracic aortic aneurysms: a population-based study. Surgery 1982, 92:1103-1108.
3. El-Hamamsy I., Yacoub M.H. Cellular and molecular mechanisms of thoracic aortic aneurysms. Nat Rev Cardiol 2009, 6:771-786.
4. Roberts W.C. The congenitally bicuspid aortic valve. A study of 85 autopsy cases. Am J Cardiol 1970, 26:72-83.
5. Guo D.C., Pannu H., Tran-Fadulu V., et al. Mutations in smooth muscle alpha-actin (ACTA2) lead to thoracic aortic aneurysms and dissections. Nat Genet 2007, 39:1488-1493.
6. Milewicz D.M., Guo D.C., Tran-Fadulu V., et al. Genetic basis of thoracic aortic aneurysms and dissections: focus on smooth muscle cell contractile dysfunction. Annu Rev Genomics Hum Genet 2008, 9:283-302.
7. Pannu H., Tran-Fadulu V., Milewicz D.M. Genetic basis of thoracic aortic aneurysms and aortic dissections. Am J Med Genet C: Semin Med Genet 2005, 139C:10-16.
8. Zhu L., Vranckx R., Khau Van Kien P., et al. Mutations in myosin heavy chain 11 cause a syndrome associating thoracic aortic aneurysm/aortic dissection and patent ductus arteriosus. Nat Genet 2006, 38:343-349.
9. Borges L.F., Touat Z., Leclercq A., et al. Tissue diffusion and retention of metalloproteinases in ascending aortic aneurysms and dissections. Hum Pathol 2009, 40:306-313.
10. Lesauskaite V., Tanganelli P., Sassi C., et al. Smooth muscle cells of the media in the dilatative pathology of ascending thoracic aorta: morphology, immunoreactivity for osteopontin, matrix metalloproteinases, and their inhibitors. Hum Pathol 2001, 32:1003-1011.
11. Nataatmadja M., West M., West J., et al. Abnormal extracellular matrix protein transport associated with increased apoptosis of vascular smooth muscle cells in marfan syndrome and bicuspid aortic valve thoracic aortic aneurysm. Circulation 2003, 108(Suppl. 1):II329-II334.
12. Longo G.M., Xiong W., Greiner T.C., et al. Matrix metalloproteinases 2 and 9 work in concert to produce aortic aneurysms. J Clin Invest 2002, 110:625-632.
13. Goodall S., Crowther M., Hemingway D.M., Bell P.R., Thompson M.M. Ubiquitous elevation of matrix metalloproteinase-2 expression in the vasculature of patients with abdominal aneurysms. Circulation 2001, 104:304-309.
14. Ikonomidis J.S., Jones J.A., Barbour J.R., et al. Expression of matrix metalloproteinases and endogenous inhibitors within ascending aortic aneurysms of patients with bicuspid or tricuspid aortic valves. J Thorac Cardiovasc Surg 2007, 133:1028-1036.
15. Guo D.C., Papke C.L., He R., Milewicz D.M. Pathogenesis of thoracic and abdominal aortic aneurysms. Ann N Y Acad Sci 2006, 1085:339-352.
16. He R., Guo D.C., Sun W., et al. Characterization of the inflammatory cells in ascending thoracic aortic aneurysms in patients with Marfan syndrome, familial thoracic aortic aneurysms, and sporadic aneurysms. J Thorac Cardiovasc Surg 2008, 136:922-929. [929, e921].
17. Liao S., Curci J.A., Kelley B.J., Sicard G.A., Thompson R.W. Accelerated replicative senescence of medial smooth muscle cells derived from abdominal aortic aneurysms compared to the adjacent inferior mesenteric artery. J Surg Res 2000, 92:85-95.
18. Wilson W.R., Herbert K.E., Mistry Y., et al. Blood leucocyte telomere DNA content predicts vascular telomere DNA content in humans with and without vascular disease. Eur Heart J 2008, 29:2689-2694.
19. Shimizu K., Mitchell R.N., Libby P. Inflammation and cellular immune responses in abdominal aortic aneurysms. Arterioscler Thromb Vasc Biol 2006, 26:987-994.
20. Isselbacher E.M. Thoracic and abdominal aortic aneurysms. Circulation 2005, 111:816-828.
21. Jones J.A., Beck C., Barbour J.R., et al. Alterations in aortic cellular constituents during thoracic aortic aneurysm development: myofibroblast-mediated vascular remodeling. Am J Pathol 2009, 175:1746-1756.
22. Phillippi J.A., Klyachko E.A., Kenny J.P., et al. Basal and oxidative stress-induced expression of metallothionein is decreased in ascending aortic aneurysms of bicuspid aortic valve patients. Circulation 2009, 119:2498-2506.
23. Hoshina K., Koyama H., Miyata T., et al. Aortic wall cell proliferation via basic fibroblast growth factor gene transfer limits progression of experimental abdominal aortic aneurysm. J Vasc Surg 2004, 40:512-518.
24. Atturu G., Brouilette S., Samani N.J., et al. Short leukocyte telomere length is associated with abdominal aortic aneurysm (AAA). Eur J Vasc Endovasc Surg 2010, 39:559-564.
25. Seipelt R.G., Backer C.L., Mavroudis C., et al. Local delivery of osteopontin attenuates vascular remodeling by altering matrix metalloproteinase-2 in a rabbit model of aortic injury. J Thorac Cardiovasc Surg 2005, 130:355-362.
26. Barbour J.R., Spinale F.G., Ikonomidis J.S. Proteinase systems and thoracic aortic aneurysm progression. J Surg Res 2007, 139:292-307.
27. Golledge J., Muller J., Shephard N., et al. Association between osteopontin and human abdominal aortic aneurysm. Arterioscler Thromb Vasc Biol 2007, 27:655-660.
28. Majumdar R., Miller D.V., Ballman K.V., et al. Elevated expressions of osteopontin and tenascin C in ascending aortic aneurysms are associated with trileaflet aortic valves as compared with bicuspid aortic valves. Cardiovasc Pathol 2007, 16:144-150.
29. Lesauskaite V., Epistolato M.C., Castagnini M., Urbonavicius S., Tanganelli P. Expression of matrix metalloproteinases, their tissue inhibitors, and osteopontin in the wall of thoracic and abdominal aortas with dilatative pathology. Hum Pathol 2006, 37:1076-1084.
30. Bruemmer D., Collins A.R., Noh G., et al. Angiotensin II-accelerated atherosclerosis and aneurysm formation is attenuated in osteopontin-deficient mice. J Clin Invest 2003, 112:1318-1331.
31. Isoda K., Nishikawa K., Kamezawa Y., et al. Osteopontin plays an important role in the development of medial thickening and neointimal formation. Circ Res 2002, 91:77-82.
32. Kato R., Momiyama Y., Ohmori R., et al. Prognostic significance of plasma osteopontin levels in patients undergoing percutaneous coronary intervention. Circ J 2009, 73:152-157.
33. Scatena M., Liaw L., Giachelli C.M. Osteopontin: a multifunctional molecule regulating chronic inflammation and vascular disease. Arterioscler Thromb Vasc Biol 2007, 27:2302-2309.